AxoGen Q2 revenue up 18.3%, beats estimates

AxoGen

05/08/2025 12:37

Overview

AxoGen Q2 revenue rises 18.3% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 beats consensus, reflecting improved operational performance

Co raises full-year revenue growth guidance to at least 17%

Outlook

AxoGen raises full-year revenue guidance to at least 17% growth

Company expects 2025 revenue of $219 mln

AxoGen anticipates gross margin of 73% to 75% for 2025

Company expects net cash flow positive for full year

Result Drivers

BROAD-BASED GROWTH - AxoGen reports double-digit revenue growth across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast

EXPANDED COVERAGE - Co adds 10 mln new covered lives for nerve repair solutions, increasing total coverage to over 55% among commercial payers

GROSS MARGIN IMPROVEMENT - Gross margin increased to 74.2%, reflecting improved operational efficiency

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$56.70 mln
$52.70 mln (8 Analysts)
Q2 Adjusted EPS
Beat
$0.12
$0.06 (6 Analysts)
Q2 Adjusted Net Income
$5.70 mln
Q2 Net Income
$600,000
Q2 Adjusted EBITDA
$9.30 mln
Q2 Gross Margin
74.2%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for AxoGen Inc is $24.00, about 47.7% above its August 4 closing price of $12.55

The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 46 three months ago

Press Release: ID:nGNX34VxTM

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)